Trial Profile
Role of Linagliptin in Improving Renal Failure by Improving CD34+ Stem Cell Number, Function and Gene Expression in Renal Function Impaired Type 2 Diabetes Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Jan 2023
Price :
$35
*
At a glance
- Drugs Linagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Biomarker; Pharmacodynamics
- 23 Mar 2021 Results of comparative analysis using 2 separte studies with Canagliflozin,and Linagliptin based on the effect of the medications on CD34+ve hematopoetic progenitor cell function such as migration, colony formation and podocyte specific urine exosome analysis, presented at the 103rd Annual Meeting of the Endocrine Society.
- 16 Jun 2020 Results presented at the 80th Annual Scientific Sessions of the American Diabetes Association
- 03 Feb 2020 Status changed from active, no longer recruiting to completed.